Baseline Genotypic and Phenotypic Susceptibilities of HIV-1 Group O to Enfuvirtide | Zendy

Agnès Depatureaux | Zendy; Charlotte Charpentier | Zendy; Gilles Collin | Zendy; Marie Leoz | Zendy; Diane Descamps | Zendy; Aurélia Vessière | Zendy; Florence Damond | Zendy; Dominique Rousset | Zendy; Françoise BrunVézinet | Zendy; JeanChristophe Plantier | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Baseline Genotypic and Phenotypic Susceptibilities of HIV-1 Group O to Enfuvirtide

Author(s) -

Agnès Depatureaux,

Charlotte Charpentier,

Gilles Collin,

Marie Leoz,

Diane Descamps,

Aurélia Vessière,

Florence Damond,

Dominique Rousset,

Françoise BrunVézinet,

JeanChristophe Plantier

Publication year - 2010

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00100-10

Subject(s) - enfuvirtide , genotype , biology , virology , phenotype , human immunodeficiency virus (hiv) , drug resistance , gp41 , genetics , gene , antigen , epitope

We assessed the natural genotypic and phenotypic susceptibilities to enfuvirtide of 171 HIV group O (HIV-O) samples and 29 strains, respectively. The N42D resistance-associated mutation in the gp41 region was detected in 98% of cases. The phenotypic assay showed a wide range of baseline susceptibilities, with 50% inhibitory concentrations (IC50 s) from 4 to 5,000 nM, a range similar to that reported for HIV-1 group M. Thus, despite the natural genotypic resistance conferred by the N42D signature mutation, HIV-O variants appear to be phenotypically susceptible. Enfuvirtide could therefore potentially be used in antiretroviral treatments for HIV-O-infected patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research